Adeno-associated virus 2 (AAV) vectors are currently in use in Phase I/II clinical trials for gene therapy of cystic fibrosis and hemophilia B. Although 100% of murine hepatocytes can be targeted by AAV vectors, the transgene expression is limited to B5% of hepatocytes. Since the viral genome is a single-stranded DNA, and single strands of both polarities are encapsidated with equal frequency, it has been suggested that failure to undergo DNA strandannealing accounts for the lack of efficient transgene expression. We and others, on the other hand, have proposed that failure to undergo viral second-strand DNA synthesis attributes to the observed low efficiency of transgene expression. We have previously documented that a cellular protein, designated FKBP52, when present in phosphorylated forms, inhibits the viral second-strand DNA synthesis, and consequently, limits transgene expression in nonhepatic cells, whereas unphosphorylated forms of FKBP52 have no effect. To further evaluate whether phosphorylated FKBP52 is also involved in regulating AAV-mediated transgene expression in murine hepatocytes, we generated transgenic mice overexpressing the cellular T-cell protein tyrosine phosphatase (TC-PTP) protein, known to catalyze dephosphorylation of FKBP52, as well as mice deficient in FKBP52. We demonstrate here that dephosphorylation of FKBP52 in TC-PTP transgenic (TC-PTP-TG) mice, and removal of FKBP52 in FKBP52-knockout (FKBP52-KO) mice results in efficient transduction of murine hepatocytes following tail-vein injection of recombinant AAV vectors. We also document efficient viral second-strand DNA synthesis in hepatocytes from both TC-PTP-TG and FKBP52-KO mice. Thus, our data strongly support the contention that the viral second-strand DNA synthesis, rather than DNA strand-annealing, is the ratelimiting step in the efficient transduction of hepatocytes, which should have implications in the optimal use of recombinant AAV vectors in human gene therapy.
Adeno-associated virus 2 (AAV) vectors are currently in use in Phase I/II clinical trials for gene therapy of cystic fibrosis and hemophilia B. Although 100% of murine hepatocytes can be targeted by AAV vectors, the transgene expression is limited to B5% of hepatocytes. Since the viral genome is a single-stranded DNA, and single strands of both polarities are encapsidated with equal frequency, it has been suggested that failure to undergo DNA strandannealing accounts for the lack of efficient transgene expression. We and others, on the other hand, have proposed that failure to undergo viral second-strand DNA synthesis attributes to the observed low efficiency of transgene expression. We have previously documented that a cellular protein, designated FKBP52, when present in phosphorylated forms, inhibits the viral second-strand DNA synthesis, and consequently, limits transgene expression in nonhepatic cells, whereas unphosphorylated forms of FKBP52 have no effect. To further evaluate whether phosphorylated FKBP52 is also involved in regulating AAV-mediated transgene expression in murine hepatocytes, we generated transgenic mice overexpressing the cellular T-cell protein tyrosine phosphatase (TC-PTP) protein, known to catalyze dephosphorylation of FKBP52, as well as mice deficient in FKBP52. We demonstrate here that dephosphorylation of FKBP52 in TC-PTP transgenic (TC-PTP-TG) mice, and removal of FKBP52 in FKBP52-knockout (FKBP52-KO) mice results in efficient transduction of murine hepatocytes following tail-vein injection of recombinant AAV vectors. We also document efficient viral second-strand DNA synthesis in hepatocytes from both TC-PTP-TG and FKBP52-KO mice. Thus, our data strongly support the contention that the viral second-strand DNA synthesis, rather than DNA strand-annealing, is the ratelimiting step in the efficient transduction of hepatocytes, which should have implications in the optimal use of recombinant AAV vectors in human gene therapy. The adeno-associated virus 2 (AAV) genome is a singlestranded DNA, which is transcriptionally inactive. Since single-stranded viral genomes of either polarity are encapsidated with equal frequency, 1 it has been suggested that following infection, DNA strand-annealing renders the viral genomes transcriptionally active. 2, 3 Others and we, on the other hand, have suggested that viral second-strand DNA synthesis is the rate-limiting step in AAV-mediated transgene expression. [4] [5] [6] [7] [8] [9] [10] [11] We previously observed that following intravenous (i.v.) administration into the tail-vein, AAV vectors selectively target the liver in mice, but less than 5% of hepatocytes express the transgene. 12 These studies were subsequently corroborated by other investigators. [13] [14] [15] [16] However, it is not entirely clear why the remainder of the 95% of hepatocytes do not allow transgene expression despite being AAV DNA positive. 13, [17] [18] [19] In our previous studies, we have identified that a 52 kDa cellular protein, FKBP52, which binds the immunosuppressant drug FK506, 20, 21 interacts specifically with the D-sequence within the inverted terminal repeat (ITR) of the AAV genome. 8 FKBP52 is phosphorylated at tyrosine residues by the cellular epidermal growth factor receptor protein tyrosine kinase (EGFR-PTK). Phosphorylated FKBP52 inhibits the viral second-strand DNA synthesis leading to inefficient transgene expression. [6] [7] [8] [9] [10] [11] We have also documented that FKBP52 is dephosphorylated at tyrosine residues by the cellular T-cell protein tyrosine phosphatase (TC-PTP), 22 ,23 which leads to efficient viral second-strand DNA synthesis and a significant increase in AAV-mediated transduction efficiency in established human cell lines as well as in primary hematopoietic stem cells from TC-PTP-transgenic mice. 9 In our current studies, we have examined the efficiency of AAV-mediated transgene expression in murine hepatocytes following i.v. administration of recombinant AAV vectors carrying the enhanced green fluorescent protein (AAV-EGFP) in FKBP52-knockout (FKBP52-KO) mice and in transgenic mice that express either the wild-type (wt) TC-PTP (wtTC-PTP-TG) or a mutant TC-PTP (mTC-PTP-TG) gene. In mTC-PTP, the cysteine residue in the active site had been changed to a serine residue. 12-16 After 2 weeks, liver sections from three hepatic lobes were observed under a confocal scanning fluorescence microscope. These results are shown in Figure 1 . It is evident that whereas no green fluorescence was observed in livers from mock-injected animals, AAV transduction efficiency in primary hepatocytes from mTC-PTP-TG mice was low, and similar to nontransgenic normal mice (not shown), as observed previously. [12] [13] [14] [15] [16] However, hepatocytes from wtTC-PTP-TG and FKBP52-KO mice were transduced by AAV vectors with significantly higher efficiency 2-weeks postinjection. Quantitative analyses of AAV transduction efficiency of hepatocytes from TC-PTP-TG and FKBP52-KO mice, shown in Figure 2 , indicate that the transgene expression increased B15-and B4-fold 1 week postinjection; B17-and B7-fold 2 weeks postinjection; and B16-and B12-fold 4 weeks postinjection in TC-PTP-TG and FKBP52-KO mice, respectively. These data support our contention that TC-PTP-mediated tyrosine dephosphorylation of FKBP52 is a crucial determinant of AAV transduction efficiency. The lower transduction efficiency in hepatocytes from FKBP52-KO mice is due, at least in part, to impaired intracellular trafficking of AAV vectors in these cells, as we have observed in primary hematopoietic cells from these mice (Z Yang, L Zhong, W Li, KY Qing, Y Li, LY Chen, MQ Tan, MC Yoder, W Shou, and A Srivastava; Mol Ther 2003; 7: S14).
In order to identify the cell type in the liver transduced by the AAV vector, immunofluorescence assays were performed using mouse albumin (hepatocyte-specific) and CD31 (endothelial cell-specific) antibodies. Liver sections from hepatic lobes of mock-injected and vectorinjected mice 2 weeks postinjection were labeled with Alexa Fluor 546-conjugated rat anti-mouse CD31 monoclonal antibodies, and Alexa Fluor 647-conjugated goat anti-mouse albumin polyclonal antibodies, and images were obtained using laser scanning confocal microscopy. As can be seen in Figure 3 , AAV vector-mediated EGFP expression (green) in liver sections from vector-injected mice colocalized with albumin (red) but not with CD31 (blue) expression. Thus, consistent with previously published reports, [12] [13] [14] [15] [16] AAV vectors selectively transduce hepatocytes.
We next examined whether the increase in AAV transduction efficiency in wtTC-PTP-TG and FKBP52-KO mice was due to more efficient strand-annealing or viral second-strand DNA synthesis. Low M r DNA samples were isolated from liver tissues of these mice 1, 2 and 4 weeks postinjection, and electrophoresed on 1% alkaline-agarose gels followed by Southern blot analyses using a 32 P-labeled EGFP DNA probe as previously described. 25, 26 As can be seen in Figure 4 , whereas no signal was detected in mock-injected mice (lanes 1, 5, 9 ), Figure 1 AAV-mediated transduction of hepatocytes from TC-PTP-TG and FKBP52-KO mice. Transgenic mice overexpressing the murine wt or the C-S mutant TC-PTP gene were generated as described previously.
9 TC-PTP-TG mice were identified by PCR amplification of genomic DNA sample from tail snips using the murine TC-PTP cDNA-specific primerpair (5 0 -CGGTTAAATGTGCACAGTACTGGCC-3 0 and 5 0 -CTACAAC GAGAAGGTGCGAGAGC-3 0 ) followed by Southern blot hybridization using a 32 P-labeled TC-PTP DNA probe as described previously. 25, 26 The generation and characterization of FKBP52-KO mice will be described elsewhere (Z Yang and W Shou, manuscript in preparation). The null mutation of FKBP52-KO mice was confirmed by Northern and Western blots and RT-PCR analyses (not shown). Highly purified stocks of a recombinant AAV vector containing the EGFP reporter gene driven by the cytomegalovirus (CMV) immediate-early promoter (vCMVp-EGFP) were purchased from Virapur, LLC (La Jolla, CA, USA). Recombinant expression plasmids containing the Rous sarcoma virus (RSV) promoterdriven murine TC-PTP cDNA, either the wild type (wt TC-PTP), or a mutant, in which the catalytic cysteine residue in the active site had been replaced with a serine residue (mutant TC-PTP), were generously provided by Dr Michel Tremblay (McGill University, Montreal, Quebec, Canada). Recombinant AAV-EGFP vectors were injected intravenously via the tailvein into C57B6 mice, wtTC-PTP-TG or mTC-PTP-TG and FKBP52-KO mice at 1 Â 10 11 viral physical particles per animal. Liver sections from three hepatic lobes of mock-injected and vector-injected mice after 2 weeks postinjection were mounted on slides. Images were obtained using an MRC1024 laser scanning confocal microscope (Bio-Rad Microscopy Division, Cambridge, MA, USA) equipped with a Krypton-Argon (488 nm) attached to a Nikon Diaphot inverted microscope (Fryer Co., Huntley, IL, USA). 3D series (Z series) were obtained by imaging serial confocal planes (25 planes at 2 mm intervals) at 512 Â 512 pixel resolution with a Nikon 20 Â water-immersion objective. Optical sectioning was performed along the XYZ axis. Projections of the Z-stacks were generated at 512 Â 512 pixel resolution with a 20 Â water-immersion objective (2 mm intervals). Composite images were assembled in MetaMorph imaging series 5.0 software (Universal Imaging, Downingtown, PA, USA) and Adobe Photoshop 5.0 (Adobe Systems, Inc., San Jose, CA, USA).
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L Zhong et al almost all of the input AAV vector genomes was present as single-stranded (ss) DNA in hepatocytes from mTC-PTP-TG transgenic mice (lanes 2, 6, 10), similar to that observed in nontransgenic normal mice, and consistent with the observed low-transduction efficiency of recombinant AAV vectors in the murine hepatocyts.
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Interestingly, a significant fraction of the viral genomes was converted to dimer-length DNA forms (d), which migrated slower on the denaturing gel, 1 week after injection, and most of them were converted to dimerlength forms 2-and 4 weeks postinjection in wtTC-PTP-TG mice (lanes 3, 7, 11). Viral second-stand DNA synthesis could also be observed in hepatocytes from FKBP52-KO mice (lanes 4, 8, 12 ), albeit at a lower level at 1-and 2 weeks postinjection, the underlying basis of which remains unclear. It is possible that proteins other than FKBP52 are being dephosphorylated at tyrosine residues by TC-PTP, and these might be contributing to the observed effect. However, our attempts to document compensatory binding of a putative D-sequence-binding protein in cells derived from FKBP52-KO mice yielded negative results (data not shown). Regardless of the mechanism involved, the extent of viral second-strand DNA synthesis was consistent with the observed transcriptional activity of the vector genomes. [4] [5] [6] [7] [8] [9] [10] [11] These data strongly argue that rather than strand-annealing, TC-PTP-mediated tyrosine dephosphorylation of FKBP52, or the absence of FKBP52, leads to efficient AAV second-strand DNA synthesis resulting in an increase in AAV-mediated transgene expression in hepatocytes in vivo.
Although our data might appear at odds with the model proposed by Nakai et al, 2 which favors DNA strand-annealing as the mechanism of hepatocyte transduction, the simplest explanation is that viral secondstrand DNA synthesis is the rate-limiting step in B95% of hepatocytes, whereas DNA strand-annealing might be operative in B5% of hepatocytes. It is intriguing, however, as to what prevents DNA strand-annealing in the majority of hepatocytes. It is possible, but not likely, that phosphorylated forms of FKBP52 inhibit AAV DNA strand-annealing. Our data, presented here, are consistent with recently published reports 28, 29 as well as those obtained by Samulski and co-workers using singlepolarity AAV vectors, which transduce murine muscle cells efficiently, even in the complete absence of DNA strand-annealing (RJ Samulski, personal communication). Furthermore, using the same single-polarity AAV vectors, we have also documented high-efficiency transduction in HeLa cells stably transfected with a TC-PTP expression plasmid in vitro, and in primary hepatocytes in TC-PTP-TG and FKBP52-KO mice in vivo (unpublished results).
Taken together, these data strongly support the notion that the lack of transgene expression in the majority of Figure 3 Identification of the cell type in murine livers expressing the transgene following AAV-mediated gene transfer. Hepatic lobes of mockinjected and vector-injected mice were dissected 2 weeks postinjection and sections were mounted onto glass slides. EGFP expression was detected by confocal microscopy as described in the legend to Figure 1 . Slides were washed with PBS, and sections were fixed using 4% paraformaldehyde/ PBS at 41C for 1 h, and washed three times with PBS. Liver sections were then immersed in PBS containing 3% milk, 0.05% Triton-X 100 (PMT solution) for 30 min to block nonspecific protein interactions and to permeabilize the cell membranes. Rat anti-mouse CD31 monoclonal antibodies (BD Biosciences, Pharmingen, San Diego, CA, USA) and goat anti-mouse albumin polyclonal antibodies (Bethyl Laboratory, Inc., Montgomery, TX, USA) were conjugated to Alexa Fluor 546 and 647, respectively, using the manufacturer's protocol (Molecular Probes, Eugene, OR, USA). Liver sections were labeled with conjugated CD31 and albumin antibodies in PMT solution, and incubated at 41C overnight. Slides were washed and images were obtained using an MRC1024 laser scanning confocal microscope. Projections of the Z-stacks were generated at 512 Â 512 pixel resolution with a Nikon 100 Â water-immersion objective (2 mm intervals). Composite images were assembled in MetaMorph imaging series 5.0 software (Universal Imaging, Downingtown, PA, USA) and Adobe Photoshop 5.0 (Adobe Systems, Inc., San Jose, CA, USA) as described in the legend to Figure 1 . Figure 2 Quantitative analysis of AAV transduction efficiency of hepatocytes from TC-PTP-TG and FKBP52-KO mice. Images from three visual fields of mock-injected and vector-injected mice after 1-, 2-, and 4 weeks postinjection were analyzed quantitatively by ImageJ analysis software (NIH, Bethesda, MD, USA). Transgene expression was assessed as total area of green fluorescence (pixel 2 ) per visual field (mean7s.d.). Analysis of variance (ANOVA) was used to compare between test results and the control, and were determined to be statistically significant.
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hepatocytes is due to failure of the AAV genome to undergo second-strand DNA synthesis, which is blocked by the tyrosine-phosphorylated forms of FKBP52. Since TC-PTP catalyzes tyrosine dephosphorylation of FKBP52, it is conceivable that the use of recently described self-complementary AAV (scAAV) vectors [27] [28] [29] carrying the TC-PTP gene would be exploitable to augment the transduction efficiency of conventional AAV vectors provided that deliberate expression of TC-PTP is not deleterious in primary cells. We have thus far not detected any toxicity in our TC-PTP-TG mice, 9 who remain fertile and healthy more than 1 year of age. 3 g ) from either mock-injected or vectorinjected mice, obtained at various indicated times, were immediately frozen in liquid nitrogen and homogenized by an alloy tool steel mortar and pestle set (Fisher, Chicago, IL, USA). Low-M r DNA samples were isolated and electrophoresed on 1% alkaline-agarose gels followed by Southern blot hybridization using a 32 P-labeled EGFP DNA probe as described previously. 25, 26 m and d denote the unit-length single-stranded and dimmer-length single-stranded AAV genomes, respectively.
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